The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Patterson Leone D since 2019.
This trader's CIK number is 1233539.
At the time of last reporting, Patterson Leone D was the Chief Fin. and Bus. Officer of Tenaya Therapeutics, Inc.. (stock ticker symbol TNYA).
Also see all insider trading activities at Tenaya Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2021 | ADVM | 0 | $0 | 12,533 | $176,965 | 0 | $0 |
2020 | ADVM | 0 | $0 | 73,171 | $1,132,109 | 44,424 | $152,818 |
2019 | ADVM | 0 | $0 | 40,000 | $428,800 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | TNYA | 0 | $0 | 5,201 | $30,477 | 0 | $0 |
2023 | TNYA | 0 | $0 | 4,452 | $16,962 | 0 | $0 |
1. Adverum Biotechnologies, Inc. (ADVM)
2. Tenaya Therapeutics, Inc. (TNYA)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2021-02-09 | ADVM | Sale | 12,533 | 14.12 | 176,965 |
2020-06-16 | ADVM | Sale | 13,171 | 24.68 | 325,060 |
2020-05-06 | ADVM | Option Ex | 20,000 | 3.44 | 68,800 |
2020-05-06 | ADVM | Sale | 20,000 | 20.02 | 400,400 |
2020-03-20 | ADVM | Sale | 39,526 | 10.17 | 401,900 |
2020-03-20 | ADVM | Option Ex | 24,424 | 3.44 | 84,018 |
2020-03-17 | ADVM | Sale | 474 | 10.02 | 4,749 |
2019-12-23 | ADVM | Sale | 40,000 | 10.72 | 428,800 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-02-16 | TNYA | Sale | 5,201 | 5.86 | 30,477 |
2023-08-16 | TNYA | Sale | 4,452 | 3.81 | 16,962 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Patterson Leone D (Chief Fin. and Bus. Officer of Tenaya Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.